Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol for prevention of COPD exacerbations
ChiCTR1900022146Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of umifenovir in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Frequency of moderate or severe acute exacerbation in patients with chronic obstructive pulmonary disease. Started Jan 2019; status: recruiting.
02
Drugs
umifenovir
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR1900022146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022146.